Pfizer Inc. $PFE Stake Cut by Castle Wealth Management LLC

Castle Wealth Management LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 9.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,679 shares of the biopharmaceutical company’s stock after selling 889 shares during the period. Castle Wealth Management LLC’s holdings in Pfizer were worth $210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter valued at $28,000. North Capital Inc. bought a new stake in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the second quarter valued at $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the first quarter valued at $35,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PFE shares. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

NYSE:PFE opened at $24.72 on Thursday. The business’s 50-day moving average price is $24.88 and its 200 day moving average price is $24.13. The firm has a market cap of $140.52 billion, a P/E ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.